Prognostic study reveals CCL22 as an independent marker in endometrial cancer patients, highlighting its link to immunosuppressive regulatory T-cell invasion.
The chemokine CCL22 is recognized for recruiting immunosuppressive regulatory T-cells (Treg) that contribute to disease progression in various tumor entities helping them to evade the host immune response. Our study aims to identify the expressing cell types and to evaluate the prognostic significance of CCL22 secretion and its association with Treg invasion in endometrial cancer (EC), an immunogenic cancer.
No takes yet. Share an insight, caveat, or question.
Mannewitz et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: